ReviewBasic & clinical pharmacology & toxicology2025
Models of Endocrine-Disrupting Effects: Human Placental Steroidogenesis.
Review in Basic & clinical pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Steroidogenic compensation and lipid deficiency with enhanced NADThe FEBS journal · 2026Article
- Placental dysfunction reflects endocrine impairment and trophoblast alterations in polycystic ovarian syndrome.Scientific reports · 2026Article
- Replacement bisphenols, phthalates, and micro-/nanoplastic exposures in human reproductive endocrinology.Frontiers in endocrinology · 2026Review
- New approach methodologies (NAMs) for improved developmental and reproductive toxicity (DART) assessment with focus on endocrine disruption - a PARC project.Frontiers in toxicology · 2026Review
- Models of Endocrine-Disrupting Effects: Human Placental Steroidogenesis.Basic & clinical pharmacology & toxicology · 2025Review
- Strategy advancements in placental pharmacokinetics: fromFrontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endocrine disruption during pregnancy has gained increasing interest as epidemiological studies report associations of exposures and adverse effects on fetal growth, followed by effects on the growing child and ultimately in the adult. When studying endocrine disruption during pregnancy, the placental steroidogenesis is difficult to model, as the human placenta is unique in the pathway of cellular uptake of cholesterol, the high levels of progesterone production and the expression of aromatase. Models to test for endocrine disruption should respect species differences, with preference to human models for human risk assessment. Here, we present existing research of placental steroidogenesis and other placental hormones using human placental models: placental perfusion, placental explants, fragments, microsomes and vesicles, primary cell culture, stem cells, placenta on a chip and choriocarcinoma cell cultures: BeWo, HTR-8/SVneo, Jar, JEG-3 and ACH-3P. We conclude that there is a lack of research focused on placental steroidogenesis and the effects of endocrine-disrupting compounds. Advantages and limitations of existing models are discussed, and future directions suggested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.